Wednesday, September 07, 2016
Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced plans to establish an automated manufacturing operation in the United States and to build product beginning in 2019.
The new U.S. operation is intended to provide manufacturing redundancy and additional production capacity to support growth and new product launches. The new operation will enable further improvements of manufacturing reliability and the lowering of production costs, in line with the Company’s previously stated objectives.
“The establishment of our U.S. manufacturing operation will support our goal to be a world-class high-quality, high-volume, low-cost manufacturer. We are making this investment to provide redundancy and additional capacity to support our exciting growth plans,” said Patrick Sullivan, President and Chief Executive Officer. “This highly-automated operation will accelerate efficiency and effectiveness of our global manufacturing operations and supply chain and help pave the way to gross margin of over 65% in the coming years.”
Source : finance.yahoo.com
